NCT05626322View on ClinicalTrials.gov

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

August 12, 2024

Study Completion Date

May 1, 2025

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Maplirpacept

Intravenous infusion

DRUG

Tafasitamab

Intravenous infusion

DRUG

Lenalidomide

Oral (by mouth)

Trial Locations (7)

48109

University of Michigan, Ann Arbor

49201

Dong-A University Hospital, Busan

70809

Mary Bird Perkins Cancer Center, Baton Rouge

02903

Lifespan Cancer Institute, Providence

02906

The Miriam Hospital, Providence

990-9585

Yamagata University Hospital, Yamagata

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

MorphoSys AG

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05626322 - Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter